Merck introduces single-use reactor to accelerate ADC manufacturing
A rapidly advancing class of therapeutic agents, ADCs target and selectively eliminate tumour cells while sparing healthy ones. Dubbed Mobius ADC Reactor, the offering is engineered to meet